Sobi On The Look-Out For Licensing, M&A Opportunities
Swedish Orphan Biovitrum AB may be in a launch phase with first sales of its long-acting hemophilia products in Europe, but the company is already looking ahead to use its growing commercial capabilities for other products.
You may also be interested in...
Affiliate of the Swedish rare disease specialist has a goal to build the North American business to account for 50% of global sales, an effort that will involve organic growth and M&A.
Sweden’s Swedish Orphan Biovitrum and Italy’s Recordati are looking towards hemophilia and rare diseases to keep up the growth of their businesses, and Q3 results have highlighted the Swedish company in particular as a potential takeover target.
This week's Pipeline Watch, a snapshot of all the late-stage R&D and regulatory events in the pharma and biotech industries, is now available to view.